论文部分内容阅读
目的：探讨沙美特罗/丙酸氟替卡松治疗慢性阻塞性肺疾病（ COPD）的临床疗效及其对肺功能的影响。方法选取厦门大学医院2014年1月—2016年5月收治的稳定期COPD患者56例，按照就诊顺序分为试验组与对照组，各28例。试验组患者予以沙美特罗/丙酸氟替卡松干粉吸入剂治疗，对照组予以沙丁胺醇气雾剂和丙酸倍氯米松气雾剂治疗，两组患者持续治疗12周。比较两组患者改良版英国医学研究委员会量表（ mMRC）评分、肺功能指标〔用力肺活量（ FVC）、第1秒用力呼气容积（ FEV1）、FEV1/FVC〕。结果治疗前两组患者MRC量表评分比较，差异无统计学意义（ P﹥0.05）；治疗后试验组MRC评分低于对照组（ P﹤0.05）。治疗前两组患者FVC、FEV1及FEV1/FVC比较，差异无统计学意义（ P﹥0.05）；治疗后试验组FVC、FEV1及FEV1/FVC水平高于对照组（ P﹤0.05）。结论沙美特罗/丙酸氟替卡松治疗COPD的临床疗效确切，可改善患者肺功能指标，缓解患者临床症状。“,”Objective To observe the clinical effect of salmeterol/fluticasone propionate in the treatment of chronic obstructive pulmonary disease( COPD)and the influence on pulmonary function. Methods A total of 56 patients with stable COPD were selected from January 2014 to May 2016 in Xiamen University Hospital,which were randomly divided into experi-mental group and control group according to order of treatment,28 cases in each group. Experimental group was received salmet-erol/fluticasone propionate powder for inhalation therapy,the control group was received salbutamol aerosol and beclometasone dipropionate aerosol therapy,both groups were treated for 12 weeks. The mMRC score and pulmonary function index( FVC, FEV1 ,FEV1/FVC) were compared between the two groups. Results Before treatment,no significant difference of mMRC score was found between the two groups(P﹥0. 05);after treatment,experimental group of mMRC score was significantly lower than control group(P﹤0. 05). Before treatment,no significant differences of FVC,FEV1 or FEV1/FVC was found between the two groups( P﹥0. 05);after treatment,experimental group of FVC,FEV1 and FEV1/FVC were higher than control group ( P﹤0. 05). Conclusion Salmeterol/fluticasone propionate has an obviousle clinical effect in treatment of COPD,it can im-prove the pulmonary function index and relief the clinical symptoms.